Pembrolizumab and Capecitabine in Treating Patients With Locally Advanced or Metastatic Triple Negative or Hormone-Refractory Breast Cancer That Cannot Be Removed by Surgery

Conditions:   Estrogen Receptor Negative;   HER2/Neu Negative;   Progesterone Receptor Negative;   Recurrent Breast Carcinoma;   Stage III Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer;   Triple-Negati ve Breast Carcinoma Interventions:   Drug: Capecitabine;   Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab Sponsors:   Northwestern University;   Merck Sharp & Dohme Corp.;   National Cancer Institute (NCI) Not yet recruiting - verified February 2017
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials